Saturday, March 25, 2023
  • Login
Financeritual
Saturday, March 25, 2023
No Result
View All Result
  • News
  • Markets
  • Personal Finance
  • Crypto
  • FinTech
  • Luxury Life
  • Investing
Financeritual
No Result
View All Result
Advertisment
Home Markets

Three Stocks to Buy Under $10

by Jacob Delliou
July 12, 2020
in Markets
Reading Time: 4 mins read
46
SHARES
1.5k
VIEWS
Share on FacebookShare on Twitter
Advertisment

Cheap stocks tend to be riskier. But there are exceptions. These three companies offer great bull cases for those who want to spice up their portfolios.

There are so many stocks out there, people can even get lost in them. At the moment the largest companies like Amazon.com or Google parent Alphabet which trade at four-figure prices. Bear in mind that nominal prices don’t mean much – $50 stocks can be just as solid as $250 stocks.

However, typically cheap small caps or even micro-caps are cheap for a good reason. It might be compelling to buy cheap stocks because of the psychological factor; it’s nice to be able to buy many shares. What is more, these stocks are often characterized by price swings, and it seems to investors that they’ll lead to big gains in a short time.

Institutional investors do the opposite, though. Sometimes they trade once a stock dips below $10 or lower. That’s due to low nominal prices typically being a sign of higher risk – they might be in long-term decline. Even good cheap stocks carry some risk, for example, narrow revenue streams or debt.

Here you can find five cheap stocks that have promising potential. Once again: they are risky, so only invest in these what you can afford to lose.

LiveXLive Media

Jacob Delliou | All images and videos are copyrighted to their respective owners

Company’s market value: $195 million

Ever since the start of the pandemic, one of the things people miss is live music: concerts, club performances, dance-hall shows, and so on.

It’s good that in such circumstances LiveXLive Media (LIVX, $3.28) doesn’t only rely on live events. Thanks to it, the company shows more-than-doubling of shares. This digital media company that works with live music does the same thing with streaming music, internet radio, and video content.

In June 2020, LiveXLive announced record 2020 revenues of $38.7 million. That’s a significant improvement from $33.7 million in 2019. Here we have to remember that its losses growing quickly, too.

Despite everything, analyst Brian Kinstlinger has LIVX in his portfolio. He points out that the company has a new direct sales force which is driving better monetization. Another analyst, Jon Hickman, raised his price target, it is now $5.75 instead of $4.50 due to the growth of subscribers.

Evoke Pharma

Jacob Delliou | All images and videos are copyrighted to their respective owners

Company’s market value: $86.0 million

Having a pharmaceutical/biotech name or two is a must in any list of cheap stocks to buy. They are often characterized by having big quick-movement potential based on trial data.

Evoke Pharma (EVOK, $3.48) is among such names. The stock has grown more than two times this year thanks to the excitement caused by its Gimoti nasal spray, which was approved recently by the U.S. Food and Drug Administration (the FDA).

Gimoti (its generic name is metoclopramide), is unique as it’s the only nasal product (others are administered orally) approved to treat gastroparesis, which is a condition that interferes with digestion and let the stomach to contract.

This approval by the FDA gives Evoke a chance to access a $5 million credit line for the purposes of funding manufacturing and commercialization. Also, the company stands out because it virtually has no debt.

EVOK, similar to other cheap stocks, is not appreciated by Wall Street. However, analyst Raghuram Selvaraju upgraded the shares from Neutral to Buy after the FDA approval; he set a 12-month price target of $10, which is three times more than current prices.

AIM ImmunoTech

Jacob Delliou | All images and videos are copyrighted to their respective owners

Company’s market value: $83.5 million

Of course, right now both the medical community and the stock market are focused on research related to treating coronavirus. AIM ImmunoTech (AIM, $2.56) is a biotech company based in Florida with an entry in the product pool of the disease: Ampligen (rintatolimod), which is used for treating severely debilitated patients with chronic fatigue syndrome. In May, human trials to assess the effectiveness of Ampligen was authorized by the FDA, as well as interferon also called alfa-2b, which is extremely important for the progress in helping cancer patients with COVID-19.

The company has also applied to treat chronic fatigue caused by coronavirus after some evidence backing Ampligen’s effectiveness was found in Argentine. Similarly to many health and pharmaceutical companies working to fight COVID-19, AIM shares have increased in value a lot in 2020; at the start of the year it was below 60 cents, and now it’s well above $2.

The shares have received three Buy ratings from three so far. One of the latest ratings was given by Jason McCarthy; his idea about the price target is $5 per share, as he thinks that the value of Ampligen’s potential hasn’t been quite captured yet.

Tags: cheap stocksinvestingStocks
Advertisment

Related Posts

8 Proven Passive Income Streams for 2021
Markets

8 Proven Passive Income Streams for 2021

by Jacob Delliou
October 31, 2022
Markets

2 Great 5G-related Stocks to Buy Right Now

by Jacob Delliou
October 31, 2022
Markets

3 Excellent Stocks Under $10

by Jacob Delliou
October 31, 2022
Markets

Investing in Marijuana ETFs in 2020

by Jacob Delliou
July 11, 2020
Advertisment
Ads by Adsterra
Ads by Adsterra
Financeritual

We bring you the latest news on financial freedom with real-life cases, news on trends, and emerging markets. Stay informed with us and improve your well-being.

Categories

  • Crypto
  • FinTech
  • Investing
  • Luxury Life
  • Markets
  • News
  • Personal Finance
  • Uncategorized

Recent News

  • How Fintech and AI are Changing the Way We Bank and Invest in India
  • [Guide] Making Easy Money in the Indian Property Market
  • The Impact of AI on the Job Market: Preparing for Automation?
  • Privacy & Policy
  • Terms & Conditions
  • DMCA
  • Contact Us

©Financeritual. All rights reserved.

No Result
View All Result
  • News
  • Markets
  • Personal Finance
  • Crypto
  • FinTech
  • Luxury Life
  • Investing

©Financeritual. All rights reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
We use cookies on our website to give you the most relevant experience. Read More
Cookie SettingsAccept All
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT